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By convention, the term ‘‘mitochondrial diseases’’ refers to disorders of the mitochondrial respiratory chain, which is the only metabolic
pathway in the cell that is under the dual control of the mitochondrial genome (mtDNA) and the nuclear genome (nDNA). Therefore, a
genetic classification of the mitochondrial diseases distinguishes disorders due to mutations in mtDNA, which are governed by the
relatively lax rules of mitochondrial genetics, and disorders due to mutations in nDNA, which are governed by the stricter rules of
mendelian genetics.
Mutations in mtDNA can be divided into those that impair mitochondrial protein synthesis in toto and those that affect any one of the 13
respiratory chain subunits encoded by mtDNA. Essential clinical features for each group of diseases are reviewed.
Disorders due to mutations in nDNA are more abundant not only because most respiratory chain subunits are nucleus-encoded but
also because correct assembly and functioning of the respiratory chain require numerous steps, all of which are under the control of
nDNA. These steps (and related diseases) include: (i) synthesis of assembly proteins; (ii) intergenomic signaling; (iii) mitochondrial
importation of nDNA-encoded proteins; (iv) synthesis of inner mitochondrial membrane phospholipids; (v) mitochondrial motility and
fission.
D 2004 Elsevier B.V. All rights reserved.Keywords: Mitochondrial disease; Respiratory chain; mtDNA mutation; nDNA mutation‘‘Translational research’’ is the latest buzzword, which
has to be used in every grant application to entice reviewers.
Beyond faddism, however, even the most basic of researcher
hopes that his/her findings will ultimately benefit patients.
In this spirit, it seems appropriate that the proceedings of the
EBEC Meeting, dedicated to bioenergetics, be concluded by
an overview of mitochondrial diseases. Indeed, the term
‘‘mitochondrial diseases’’ refers specifically to defects of the
mitochondrial respiratory chain, the bioenergetic pathway
par excellence [1].
Mitochondrial myopathies were described in the early
1960s, when systematic ultrastructural and histochemical
studies revealed excessive proliferation of normal- or
abnormal-looking mitochondria in muscle of patients
with weakness or exercise intolerance [2,3]. Because,
with the modified Gomori trichrome stain, the areas of
mitochondrial accumulation looked purplish (Fig. 1), the0005-2728/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbabio.2004.03.014
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E-mail address: sd12@columbia.edu (S. DiMauro).abnormal fibers were dubbed ‘‘ragged-red fibers’’ (RRF)
and came to be considered the pathological hallmark of
mitochondrial disease [4]. However, it soon became
apparent that in many patients with RRF, the myopathy
is associated with symptoms and signs of brain involve-
ment, and the term ‘‘mitochondrial encephalomyopathy’’
was introduced. It also became clear that lack of RRF
in the biopsy does not exclude a mitochondrial etiology,
as exemplified by Leigh syndrome (LS), an encepha-
lopathy of infancy or childhood invariably due to
mitochondrial dysfunction but almost never accompanied
by RRF. The first biochemical evidence of a mitochon-
drial dysfunction—loose coupling of oxidation and phos-
phorylation—was reported in 1962 by Luft et al. [5] in a
young woman with non-thyroidal hypermetabolism (Luft
syndrome).
These disorders are especially interesting from the ge-
netic point of view because the respiratory chain is the only
metabolic pathway in the cell that is under the dual control
of the mitochondrial genome (mtDNA) and the nuclear
genome (nDNA). Therefore, a genetic classification of the
Fig. 1. Ragged-red fibers (RRF) revealed by the modified Gomori
trichrome stain. Abnormal accumulations of mitochondria appear as
reddish blotches, mostly at the periphery of muscle fibers (courtesy of
Dr. Eduardo Bonilla, Columbia University).
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tions in mtDNA, which are governed by the laxer rules of
mitochondrial genetics, and disorders due to mutations in
nDNA, which are governed by the stricter rules of mende-
lian genetics (Table 1).Table 1
Genetic and biochemical classification of the mitochondrial diseases
Genome Gene [mtDNA]
mtDNA single D
tRNALeu(UUR)
tRNALys
other tRNAs
ATPase6
ND1, ND4, ND6
ND1, ND4
Cyt b
COX III
nDNA
NDUF
SDHA
BCS1L
SURF1
SCO1
SCO2
COX10
COX 15
ATP 12
TP multiple D
ANT1 multiple D
Twinkle multiple D
POLG multiple D
dGK depletion
TK2 depletion
TAZ
OPA1
Abbreviations and symbols: D, deletion; KSS, Kearns–Sayre syndrome; PS, Pear
and stroke-like episodes; LS, Leigh syndrome; MILS, maternally inherited LS; G
death; adPEO, autosomal dominant progressive external ophthalmoplegia; arPE
indicates changes of mtDNA secondary to nDNA mutations (defects of intergeno
a Mutations in cyt b and COX genes can also cause multisystemic diseases.
b Plus refers to proximal weakness, neuropathy, psychiatric disorders, parkins1. Diseases due to mutations in mtDNA
Of the approximately 80 proteins that make up the
respiratory chain, 13 are encoded by mtDNA and all others
are encoded by nDNA. As indicated by the different colors
in Fig. 2, complex II, coenzyme Q, and cytochrome c are
exclusively encoded by nDNA. In contrast, complexes I, III,
IV, and V contain some subunits encoded by mtDNA: seven
for complex I (ND1–ND4, ND4L, ND5, and ND6), one for
complex III (cytochrome b), three for complex IV (COX I–
COX III), and two for complex V (ATPase6 and ATPase8).
Human mtDNA is a 16.569-kb circular, double-stranded
molecule, which contains 37 genes: 2 rRNA genes, 22
tRNA genes, and 13 structural genes encoding the respira-
tory chain subunits listed above. In the course of evolution,
mtDNA has lost much of its original autonomy and now is
the slave of nDNA, which encodes numerous factors needed
for mtDNA trascription, translation, and replication. Since
1988 (the birthdate of mitochondrial molecular pathology
[6,7]), the circle of mtDNA has become crowded with
pathogenic mutations (Fig. 3), and the principles of mito-
chondrial genetics should, therefore, be familiar to the
practicing physician.Biochemistry Clinical phenotype
x prot. synth. KSS; ocular myopathy; PS
x prot. synth. MELAS
x prot. synth. MERRF
x prot synth. multiple phenotypes
x ATP synth. NARP/MILS
x complex I LHON
x complex I myopathya
x complex III myopathya
x complex IV myopathya
x complex I LS
x complex II LS
x complex III GRACILE
x complex IV LS
x complex IV hepatoencephalomyopathy
x complex IV cardioencephalomyopathy
x complex IV nephroencephalomyopathy
x complex IV cardioencephalomyopathy
x complex V fatal infantile multisystemic
x _ MNGIE
x prot. synth. adPEO-plusb
x prot. synth. adPEO-plusb
x prot. synth. ad/arPEO-plusb
x prot. synth. hepatocerebral syndrome
x prot. synth. myopathy; SMA
x cardiolipin Barth syndrome
x mit. Motility ad optic atrophy
son syndrome; MELAS, Mitochondrial encephalomyopathy, lactic acidosis
RACILE, growth retardation, aminoaciduria, cholestasis, lactacidosis, early
O, autosomal recessive PEO; SMA, spinal muscular atrophy. [mtDNA]
mic signaling).
onism.
Fig. 2. Scheme of the respiratory chain, showing the mtDNA-encoded subunits in red and the nDNA-encoded subunits in blue. As electrons (e) flow along the
electron transport chain, protons (H+) are pumped from the matrix into the intermembrane space through complexes I, III, and IV. Protons then flow back into
the matrix through complex V, producing ATP.
S. DiMauro / Biochimica et Biophysica Acta 1658 (2004) 80–8882(i) Heteroplasmy and threshold effect. Each cell contains
hundreds or thousands of mtDNA copies, which, at cell
division, distribute randomly among daughter cells. In
normal tissues, all mtDNA molecules are identical (homo-
plasmy). Deleterious mutations of mtDNA usually affect
some but not all mtDNAs within a cell, a tissue, or an
individual (heteroplasmy). The clinical expression of a
pathogenic mtDNA mutation is largely determined by the
relative proportion of normal and mutant mtDNA genomes
in different tissues. A minimum critical number of mutant
mtDNAs is required to cause mitochondrial dysfunction in a
particular organ or tissue, resulting in a mitochondrial
disease (threshold effect).
(ii) Mitotic segregation. At cell division, the proportion
of mutant mtDNAs in daughter cells may shift and the
phenotype may change accordingly. This phenomenon,
called mitotic segregation, explains how certain patients
with mtDNA-related disorders may actually manifest differ-
ent mitochondrial diseases at different stages of their lives.
(iii) Maternal inheritance. At fertilization, all mtDNA
derives from the oocyte. Therefore, the mode of transmis-
sion of mtDNA and of mtDNA point mutations (single
deletions of mtDNA are usually sporadic events) differs
from mendelian inheritance. A mother carrying a mtDNA
point mutation will pass it on to all her children (males as
well as females), but only her daughters will transmit it to
their progeny. A disease expressed in both sexes but with no
evidence of paternal transmission is strongly suggestive of a
mtDNA point mutation. A recent surprising report cast
doubts on the rule of maternal inheritance [8], but two
simultaneous papers [9,10] and a further study from the
‘‘surprisers’’ [11] reiterated the general validity of maternal
inheritance.
The best way for the clinician to chart his course toward
a diagnosis in the clinical morass of mitochondrial diseasesis to use a classification that combines genetic and bio-
chemical criteria (Table 1). From the genetic point of view,
there are two major categories, disorders due to defects of
mtDNA and disorders due to defects of nDNA. Mutations in
mtDNA can be divided into those that impair mitochondrial
protein synthesis in toto (e.g. tRNA or rRNA genes muta-
tions and rearrangements), and those that affect one of the
13 respiratory chain subunits encoded by mtDNA.
1.1. Defects in mitochondrial protein synthesis
1.1.1. mtDNA rearrangements
Single deletions of mtDNA have been associated with
three usually sporadic conditions [12]: (i) Pearson syndrome
(PS), a rapidly fatal disorder of infancy characterized by
sideroblastic anemia and exocrine pancreas dysfunction; (ii)
Kearns–Sayre syndrome (KSS), a multisystem disorder
with onset before age 20 of impaired eye movements
(progressive external ophthalmoplegia, PEO), pigmentary
retinopathy, and heart block. Frequent additional signs
include ataxia, dementia, endocrine problems (diabetes
mellitus, short stature, hypoparathyroidism). Lactic acidosis,
elevated cerebrospinal fluid (CSF) protein (over 100 mg/dl),
and RRF in the muscle biopsy are typical laboratory
abnormalities. (iii) PEO with or without proximal limb
weakness, often compatible with a normal life span. Dele-
tions vary in size and location, but a ‘‘common’’ deletion of
5 kb is frequently seen in patients and in aged individuals.
(Fig. 3).
Duplication of mtDNA can occur in isolation or together
with single deletions and have been seen in patients with
KSS or with diabetes mellitus and deafness. Duplications
and duplications/deletions (as well as the associated phe-
notypes) are rare and usually transmitted by maternal
inheritance.
Fig. 3. Morbidity map of the human mitochondrial genome as of January 1, 2004. The map of the 16.569-kb mtDNA shows differently shaded areas
representing the protein-coding genes for the seven subunits of complex I (ND), the three subunits of cytochrome oxidase (COX), cytochrome b (Cyt b), and
the two subunits of ATP synthetase (A8/6), the 12S and 16S ribosomal RNAs (12S, 16S), and the 22 transfer RNAs (tRNA) identified by one-letter codes for
the corresponding amino acids. Diseases due to mutations that impair mitochondrial protein synthesis are shown in blue; diseases due to mutations in protein-
coding genes are shown in red. Reproduced from Ref. [1], with permission. Abbreviations: FBSN, familial bilateral striatal necrosis; KSS, Kearns–Sayre
syndrome; LHON, Leber’s hereditary optic neuropathy; MELAS, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes; MERRF,
myoclonic epilepsy with ragged-red fibers; MILS, maternally inherited Leigh syndrome; NARP, neuropathy, ataxia, retinitis pigmentosa; PEO, progressive
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Point mutations have been identified in mtDNA from
patients with a variety of disorders, most of them maternally
inherited and multisystemic, but some sporadic and tissue-
specific (Fig. 2). Among the maternally inherited encepha-
lomyopathies, two syndromes are more common.
The first is MELAS (mitochondrial encephalomyopathy,
lactic acidosis, and stroke-like episodes), which usually
presents in children or young adults after normal early
development [13]. Symptoms include recurrent vomiting,
migraine-like headache, and stroke-like episodes causing
cortical blindness, hemiparesis, or hemianopia. MRI of the
brain shows ‘‘infarcts’’ that do not correspond to the
distribution of major vessels. The most common mtDNA
mutation is A3243G in the tRNALeu(UUR) gene, but about a
dozen other mutations have been associated with MELAS,
some of which are in protein-coding genes.
external ophthalmoplegia.The second syndrome is MERRF (myoclonus epilepsy
with ragged red fibers), characterized by myoclonus, seiz-
ures, mitochondrial myopathy, and cerebellar ataxia [14].
Less common signs include dementia, hearing loss, periph-
eral neuropathy, and multiple lipomas. Three mtDNA muta-
tions, all in the tRNALys gene (A8344G, T8356C, G8363A),
have been associated with MERRF. Only one patient with a
bona fide MERRF syndrome harbored a mutation in a
different tRNA: G611A in the tRNAPhe gene [15].
Not surprisingly, syndromes associated with tRNA muta-
tions can affect every system in the body, including the eye
(optic atrophy; retinitis pigmentosa; cataracts); hearing
(neurosensory deafness); the endocrine system (short stat-
ure; diabetes mellitus; hypoparathyroidism); the heart (hy-
pertrophic cardiomyopathies; conduction blocks); the
gastrointestinal tract (exocrine pancreas dysfunction; intes-
tinal pseudo-obstruction; gastroesophageal reflux); and the
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symptoms and signs listed above should raise the suspicion
of a mitochondrial disorder, especially if there is evidence of
maternal transmission.
1.2. Defects of protein-coding genes
Also in this category, two syndromes are more common.
The first syndrome comes in two flavors: (i) NARP (neu-
uropathy, ataxia, retinitis pigmentosa) usually affects young
adults and causes retinitis pigmentosa, dementia, seizures,
ataxia, proximal weakness, and sensory neuropathy; (ii)
maternally inherited Leigh syndrome (MILS) is a more
severe infantile encephalopathy with characteristic symmet-
rical lesions in the basal ganglia and the brainstem. Both
conditions are due to mutations at nt-8993 of the ATPase6
gene [16]. The mutations also come in two flavors, T8993G
and T8993C, the T-to-G transversion being both clinically
and biochemically more deleterious than the T-to-C change
[17]. In addition, the T8993G mutation provides an excel-
lent example of the pathogenic importance of mutation load:
when the degree of heteroplasmy is moderate (around 70%),
the clinical expression is NARP, a subacute or chronic
disease of young adults, but when the degree of hetero-
plasmy is very high (about 90%), the clinical expression is a
rapidly progressive encephalopathy of infancy or childhood,
Leigh syndrome [18].
The second syndrome, LHON (Leber’s hereditary optic
neuropathy) is characterized by acute or subacute loss of
vision in young adults, more frequently males, due to
bilateral optic atrophy [19]. About a dozen different mtDNA
point mutations in structural genes have been associated
with LHON, but only three appear to be pathogenic even
when present in isolation (primary mutations) and all three
affect genes of complex I (ND genes). These are G11778A
in ND4, G3460A in ND1, and T14484C in ND6. The
exquisite vulnerability of the optic nerve in LHON and
the predominance of affected males remain to be explained
and call into question additional genetic or environmental
factors.
Interestingly, point mutations in mtDNA protein-coding
genes often escape the rules of mitochondrial genetics in
that they affect single individuals and single tissues, most
commonly skeletal muscle [20] (Fig. 2). Thus, patients with
exercise intolerance, myalgia and sometimes recurrent myo-
globinuria may have isolated defects of complex I, complex
III, or complex IV, due to pathogenic mutations in genes
encoding ND subunits, COX subunits, and especially cyto-
chrome b [21]. The lack of maternal inheritance and the
involvement of muscle alone suggest that mutations arose
de novo in myogenic stem cells after germ-layer differen-
tiation (‘‘somatic mutations’’).
Given how crowded the ‘‘morbidity map’’ of mtDNA is
(Fig. 2), we can legitimately ask whether we are scraping
the bottom of the barrel in this area. My answer is a
resounding ‘‘no’’ for the following reasons: (i) new mtDNAmutations are still being identified; (ii) accepted pathoge-
netic concepts are being challenged, including the invariably
innocent nature of homoplasmic mutations and the high
mutational load required for pathogenicity; (iii) dogmas of
mitochondrial genetics are being cracked, including—as
mentioned above—the strict maternal inheritance of
mtDNA; (iv) the functional and pathogenic importance of
mtDNA haplotypes is under intense investigation [22,23];
(v) unusual clinical phenotypes are associated with mtDNA
mutations, such as autistic spectrum disorders [24]; (vi) the
detailed pathogenesis of different encephalopathies is still
unclear.2. Diseases due to mutations in nDNA
Disorders due to mutations in nDNA are very numerous
not only because most respiratory chain subunits are nucle-
us-encoded, but also—and more importantly—because cor-
rect structure and functioning of the respiratory chain
requires many steps, all of which are under the control of
nDNA. These steps include:
(i) nuclear factors are needed for the proper assembly of
respiratory chain complexes. Mutations in these
ancillary proteins have been associated with numerous
disorders, notably Leigh syndrome.
(ii) mtDNA integrity and replication requires nDNA-
encoded factors and there has been rapid progress in
our understanding of the molecular basis of disorders
of intergenomic signaling, including syndromes asso-
ciated with multiple mtDNA deletions and mtDNA
depletion.
(iii) transport of nDNA-encoded proteins from the cyto-
plasm into mitochondria. Hereditary defects in this
complex machinery can cause mitochondrial diseases,
although only relatively few such disorders have been
documented.
(iv) the respiratory chain is embedded in the lipid bilayer of
the inner mitochondrial membrane, which is more than
a mere scaffold. Alterations of this lipid milieu can
cause disease, as illustrated by altered synthesis of
cardiolipin in Barth syndrome.
(v) mitochondria move around the cell, divide by fission,
and fuse with one another. Disorders of these essential
functions can also cause disease, as illustrated by
autosomal dominant optic neuropathy.
2.1. Mutations in genes encoding subunits or ancillary
proteins of the respiratory chain
As noted above, mtDNA encodes only 13 subunits of the
respiratory chain, while nDNA encodes all subunits of
complex II, most subunits of the other four complexes, as
well as CoQ10 and cytochrome c. Although most of the
progress in the first decade of the ‘‘molecular era’’ has been
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mendelian defects of the respiratory chain. These can affect
respiratory chain complexes directly or indirectly.
Direct ‘‘hits’’ are mutations in gene encoding respiratory
chain subunits, including subunits of complex I [25] and of
complex II [26]. These have been associated mostly with
autosomal recessive forms of Leigh syndrome. Apparently
primary coenzyme Q10 (CoQ10) deficiency can cause three
major syndromes, a predominantly myopathic disorder with
recurrent myoglobinuria, a predominantly encephalopathic
disorder with ataxia and cerebellar atrophy, and a general-
ized form [27]. Presumably, the different presentations
reflect mutations in different biosynthetic enzymes, but this
remains to be documented. Diagnosis is important because
all patients with CoQ10 deficiency respond to CoQ10
supplementation.
Indirect ‘‘hits’’ are mutations in genes encoding proteins
that are not components of the respiratory chain, but are
needed for the proper assembly and function of respiratory
chain complexes. This ‘‘murder by proxy’’ scenario is best
illustrated by mendelian defects of COX (complex IV).
Mutations in five ancillary proteins, SURF1, SCO2,
SCO1, COX10, and COX15, have been associated with
COX-deficient Leigh syndrome [28–30] or other multi-
systemic fatal infantile disorders, in which encephalopathy
is accompanied by cardiomyopathy [31,32] (SCO2,
COX15), nephropathy [33] (COX10), or hepatopathy [34]
(SCO1). Mutations in a complex III assembly protein,
BCS1L, have also been associated with Leigh-like syn-
dromes [35] and with a lethal infantile disorder dubbed
GRACILE ( growth retardation, aminoaciduria, cholestasis,
iron overload, lactacidosis, and early death) [36,37]. The
newest addition to this group of disorders is a defect of
complex V due to mutations in the assembly protein ATP12,
associated with congenital lactic acidosis and a fatal infan-
tile multisystemic disease involving brain, liver, heart, and
muscle [38].
This is a burgeoning field of research with important
theoretical and practical implications. From an investigative
point of view, these disorders are teaching us a lot about the
structural and functional complexity of the respiratory chain.
At a more practical level, identification of mutations in these
genes renders prenatal diagnosis available and suggests
approaches to therapy, such as copper administration to
infants with mutations in SCO2, a protein involved in
copper homeostasis in complex IV [39,40].
2.2. Defects of intergenomic signaling
As noted above, the mtDNA is highly dependent for its
proper function and replication on numerous factors
encoded by nuclear genes. Mutations in these genes cause
mendelian disorders characterized by qualitative or quanti-
tative alterations of mtDNA [41,42].
Examples of qualitative alterations include autosomal
dominant or autosomal recessive multiple deletions ofmtDNA, usually accompanied clinically by progressive
external ophthalmoplegia (PEO) plus a variety of other
symptoms and signs [43]. Four of these conditions have
been characterized at the molecular level. Mutations in the
gene for thymidine phosphorylase (TP) are responsible for
an autosomal recessive multisystemic syndrome called
MNGIE (mitochondrial neurogastrointestinal encephalomy-
opathy) [44,45]. Mutations in the gene encoding one iso-
form of the adenine nucleotide translocator (ANT1) have
been identified in some, but not all, patients with autosomal
dominant PEO [46]. Interestingly, both types of mutations
affect mitochondrial nucleotide pools and may have similar
pathogenic mechanisms. Mutations in a gene called Twinkle,
a helicase, are associated with autosomal dominant PEO
[47], whereas mutations in the gene encoding polymerase g
(POLG) may cause either autosomal dominant or autosomal
recessive PEO, sometimes associated with psychiatric prob-
lems or parkinsonism [48,49].
Examples of quantitative alterations of mtDNA include
severe or partial expressions of mtDNA depletion, usually
characterized clinically by congenital or childhood forms of
autosomal recessively inherited myopathy or hepatopathy
[50,51]. Although skeletal muscle and liver seem to be the
main target tissues, other tissues are often affected in both
conditions, including kidney (renal tubular acidosis) and the
central nervous system (CNS). CNS involvement often
simulates spinal muscular atrophy (SMA) and mtDNA
depletion should be considered in children with SMA
phenotype but without mutations in the SMN gene
[52,53]. Mutations in two genes, both involved in mito-
chondrial nucleotide homeostasis, have been associated with
mtDNA depletion syndromes, although they do not explain
all cases. Mutations in the gene encoding thymidine kinase
2 (TK2) are often seen in patients with myopathic mtDNA
depletion syndromes [52,54], whereas mutations in the gene
encoding deoxyguanosine kinase (dGK) predominate in
patients with hepatic or multisystemic mtDNA depletion
syndromes [55,56].
2.3. Defects of mitochondrial protein importation
Mitochondrial proteins synthesized in the cytoplasm are
provided with mitochondrial targeting signals that direct
them to the appropriate compartment within the organelle.
Transport across outer and inner membranes requires a
battery of factors, including docking proteins, chaperonins,
and proteases, and it involves unfolding and refolding of
the protein to be translocated [57]. Several mutations in
targeting sequences have been documented, preventing
individual proteins to reach their destination. In contrast,
few genetic defects are known that impair the general
transport machinery, presumably because the resulting
upheaval in mitochondrial function would not be compat-
ible with life [58]. However, at least two disorders have
been associated with mutations in components of the
transport machinery.
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syndrome (Mohr–Tranebjaerg syndrome), which is charac-
terized by neurosensory hearing loss, dystonia, cortical
blindness, and psychiatric symptoms, and is due to muta-
tions in the TIMM8A gene, which encodes the deafness-
dystonia protein (DDP1), an intermembrane space compo-
nent of the transport machinery [59].
The second is an autosomal dominant form of hereditary
spastic paraplegia due to mutations in the chaperonin
HSP60 [60].
2.4. Alterations of the lipid milieu of the inner mitochon-
drial membrane
This situation is exemplified by Barth syndrome (BTHS),
an X-linked recessive disorder characterized by mitochon-
drial myopathy, cardiopathy, growth retardation, and leuco-
penia [61]. The tafazzin (TAZ) gene responsible for this
disorder encodes a family of proteins (‘‘tafazzins’’) that are
homologous to phospholipid acyltransferases [62]. Analysis
of phospholipids in target tissues from patients with BTHS
and TAZ mutations, patients with BTHS-like syndromes
without TAZ mutations, and both normal and disease con-
trols showed decreased cardiolipin in all tissues from
genetically proven BTHS patients only [63,64]. Cardiolipin
was affected selectively and other phospholipids were
normal, and the molecular composition of cardiolipin was
altered in all tissues from BTHS patients.
2.5. Alterations of mitochondrial motility or fission
Mitochondria are dynamic organelles propelled within
the cell, sometimes long-distance (think of mitochondria
traveling to the apical end of a motor nerve from the
neuronal soma in the anterior horn of the spinal cord) by
energy-requiring dynamins along cytoskeletal microtubular
rails [65]. Mutations in a gene encoding a dynamin-related
guanosine triphosphatase (OPA1) have been associated
with an autosomal dominant form of optic atrophy result-
ing in early-onset blindness, the mendelian counterpart of
LHON [66,67]. In monocytes from these patients, mor-
phology has shown that mitochondria were clumped to-
gether rather than being uniformly distributed throughout
the cytoplasm.
2.6. Late-onset neurodegenerative diseases and aging
While there is little question that mitochondrial dysfunc-
tion (oxidative stress) has a role both in the pathogenesis of
late-onset neurodegenerative disorders, including Parkinson
disease (PD), Huntington disease (HD), Alzheimer disease
(AD), and amyotrophic lateral sclerosis (ALS), and in the
pathogenesis of what has been called ‘‘the most common
disease of all’’, aging, the relative contributions of the
nuclear genome, the mitochondrial genome, and of envi-
ronmental factors remain to be defined and probably vary indifferent conditions. Discussing this area of ‘‘mitochondrial
medicine’’ is beyond the scope of this minireview, and the
reader is referred to several comprehensive recent reviews
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